Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders

Abstract

This invention provides a method of treating a human subject suffering from a CB1 receptor related disorder comprising periodically administering to the subject an effective amount of laquinimod or pharmaceutically acceptable salt thereof in an amount effective to treat the subject.

1 . A method of treating a human subject suffering from a CB1, receptor related disorder comprising periodically administering to the subject an effective amount of laquinimod or pharmaceutically acceptable salt thereof in an amount effective to treat the subject, 
     
     
         2 . The method of  claim 1 , wherein the subject is human. 
     
     
         3 . The method of  claim 1 , wherein the CB1 receptor related disorder is ADHD, 
     
     
         4 . A method of preserving CB1 receptor sensitivity in a human subject comprising periodically administering to the subject an effective amount of laguinimod or pharmaceutically acceptable salt thereof. 
     
     
         5 . The method of  claim 1 , wherein the laguinimod is administered via oral administration. 
     
     
         6 . The method of  claim 1 , wherein the laguinimod is administered daily. 
     
     
         7 . The method of  claim 1 , wherein the laquinimod is administered more often than once daily. 
     
     
         8 . The method of  claim 1 , wherein the laguinimod is administered less often than once daily. 
     
     
         9 . The method of  claim 1 , wherein the amount of laquinimod administered is less than 0.6 mg/day. 
     
     
         10 . The method of  claim 1 , wherein the amount of laguinimod administered is 0.1-40.0 mg/day, 
     
     
         11 . The method of  claim 10 , wherein the amount of laguinimod administered is 0.1-2.5 mg/day. 
     
     
         12 . The method of  claim 10 , wherein the amount of laquinimod administered is 0.25-2.0 mg/day. 
     
     
         13 . The method of  claim 10 , wherein the amount of laquinimod administered is 0.5-1.2 mg/day. 
     
     
         14 . The method of  claim 10 , wherein the amount of laquinimod administered is 0.25 mg/day. 
     
     
         15 . The method of  claim 10 , wherein the amount of laguinimod administered is 0.3 mg/day. 
     
     
         16 . The method of  claim 10 , wherein the amount of laguinimod administered is 0.5 mg/day. 
     
     
         17 . The method of  claim 10 , wherein the amount of laquinimod administered is 0.6 mg/day. 
     
     
         18 . The method of  claim 10 , wherein the amount of laguinimod administered is 1.0 mg/day. 
     
     
         19 - 21 . (canceled) 
     
     
         22 . The method of  claim 1 , wherein the pharmaceutically acceptable salt of laquinimod is laguinimod sodium. 
     
     
         23 - 24 . (canceled) 
     
     
         25 . A pharmaceutical composition comprising an amount of laquinimod effective for use in treating a human subject suffering from a CB1 receptor related disorder and/or for preserving CB1 receptor sensitivity in a human subject. 
     
     
         26 . (canceled)